Abstract
Introduction
Incidence of type 2 diabetes mellitus (T2DM) has increased worldwide over the past years, a phenomenon often described as "epidemic" or "dramatic", thus emphasizing not only the high numbers, but also the complexity of the problem. Global projections suggest that 592 million people will have T2DM by 2035, and another 471 million people will have impaired glucose tolerance and will be at high risk of developing T2DM in subsequent years [1] .
In Romania, the prevalence is currently calculated based on a large national epidemiologic study published in 2015 [2] . Data show an overall age-and sex-adjusted prevalence of diabetes mellitus (DM) of 11.6% (95%CI 9.6%-13.6%), of which 2.4% (95%CI 1.7%-3.1%) have unknown DM.
Progressive and most probably additive by nature, the core defects of T2DM include quantitative and qualitative β-cell dysfunction, insulin resistance, and elevated glucose production in liver, as well as a decreased incretin effect and increased glucose reabsorption in kidneys. The currently available antidiabetic agents have been developed to target one or more of the underlying processes involved in T2DM. The vast majority of T2DM patients are overweight and obese, with a sedentary life and additional dangerous habits, like smoking, that put them at high cardiovascular (CV) risk. International therapeutic guidelines recommend initiation of T2DM management with lifestyle modifications and a correct diet. The first line therapy is metformin, the drug of choice, except in those patients that develop intolerance or have strict contraindications. All other anti-hyperglycemic drugs are listed as potential add-on to metformin, with no hierarchy between them. This situation may change in the near future, based on accumulating body of evidence on benefits associated with weight-neutral (Dipeptidyl Peptidase 4 (DPP-4) inhibitors) or weight-loss medications (Glucagon Like Peptide 1 (GLP-1) analogues and Sodium-glucose transporter 2 (SGLT2) inhibitors), and the harmful effects of hypoglycaemia induced by sulphonylureas [3, 4] .
Nevertheless, the aim of clinicians treating diabetes is a good glycemic control, even though many patients require multiple antidiabetic medications and sustained lifestyle changes to manage their disease.
The role of kidney in the glucose homeostasis
The kidneys are mainly involved in the glucose homeostasis through gluconeogenesis and reabsorption of glucose into the circulation from the glomerular filtrate, the latter being a major contributor to elevated glucose levels in patients with T2DM. In subjects without DM, almost the total quantity of the glucose filtered by the glomeruli is reabsorbed in the proximal tubules, such that virtually no glucose is excreted in the urine. Renal glucose reabsorption is achieved through the action of the SGLT family of protein transporters, primarily SGLT1 and SGLT2 [5] . These proteins transport glucose across the membranes of the proximal tubule epithelial cells in an active process that involves sodium transport, facilitated by the sodium gradient between the tubule and the cell, which supports secondary active co-transport of glucose. Glucose then passively diffuses into the intercellular space mainly via the GLUT2 carrier [5] .
When the concentration of glucose in plasma exceeds that which can be reabsorbed via the SGLT proteins (approximately 198 mg/dL), the excessive amount of glucose is excreted in the urine. Data from preclinical studies suggest that the hyperglycemic state in T2DM is associated with significantly higher expression of SGLT2 and GLUT2 proteins, together with an increased level of renal glucose reabsorption [6] . Chronic exposure to high blood glucose levels induce harmful metabolic effects, known as "glucose toxicity", a strong determinant of β-cell dysfunction and promoter of the vicious cycle of diabetes pathogenesis. Induction of glycosuria without affecting other metabolic parameters has led to the hypothesis, which was confirmed later on, that reversing glucose toxicity via "therapeutic glycosuria" may improve insulin sensitivity and β-cell function. That is how the SGLT2 became a novel therapeutic target for antidiabetic therapy.
SGLT2 inhibition
Located mainly in the first two segments of the proximal convoluted tubule of the kidney, SGLT2 is expressed almost entirely in the kidney and is a high-capacity, low-affinity transporter. Individuals with a naturally occurring SGLT2 dysfunction called familial renal glucosuria (an inherited disorder due to a mutation of the SGLT2 gene) have reduced renal glucose reabsorption but are typically asymptomatic, and the majority of these people appear not to experience unwanted effects [7] . Their blood glucose levels are normal and they do not have increased incidence of diabetes or renal failure.
Development of SGLT2 inhibitors started in the 19 th century with phlorizin, a substance isolated from the bark of apple tree. The molecule has proved not to be eligible for clinical development because it was poorly absorbed from the gastrointestinal tract, it was not stable enough for clinical use, and it inhibited equally SGLT1 and SGLT2 [8] . SGLT1, predominantly expressed in the small intestine transports both glucose and galactose. Inhibition of SGLT1 is associated with reduced absorption of glucose and galactose leading to potentially severe dehydration and diarrhoea [8] . SGLT2 inhibitors are indicated to improve glycemic control in adults with T2DM by reducing the reabsorption of filtered glucose. They can also lower the renal threshold for glucose, thereby increasing urinary glucose excretion. The efficacy of SGLT2 inhibitors is influenced by the level of hyperglycemia and renal function and not by insulin, their action becoming negligible when plasma concentrations drops below 90 mg/dL. This translates into a lower risk of hypoglycaemia compared with insulin-dependent antidiabetic drugs [9] .
Dapagliflozin -the only SGLT2 inhibitor currently available in Romania
Dapagliflozin (Forxiga) is the first SGLT2 inhibitor approved in the world, in 2011. It was followed in Europe by canagliflozin (Invokana) and empagliflozin (Jardiance).
Dapagliflozin is indicated for T2DM patients aged 18 years and over as monotherapy to improve glycemic control in patients with inadequate glycemic control who are intolerant to metformin, and as an adjunct to diet and exercise in combination with other glucoselowering agents in patients inadequately controlled on existing antidiabetic medications, including insulin. The only dosage currently approved in Europe is 10 mg once daily, in oral administration [10] .
In [20] showed that the improvements in glycemic parameters and reduction in body weight were maintained for up to 2 years. In a clinical study that evaluated efficacy and safety of dapagliflozin vs. glipizide in T2DM patients inadequately controlled with metformin, the results up to 4 years showed similar efficacy in reducing HbA1c and FPG levels, with a significant better safety profile in terms of hypoglycaemia and weight change for dapagliflozin vs. glipizide [21] .
Additional benefits of treatment with dapagliflozin
As already mentioned, moderate weight reduction has been a consistent finding in patients treated with dapagliflozin. Because dapagliflozin appears to have a mild diuretic effect [22] , the weight loss could result from fluid loss secondary to osmotic diuresis; it could also be attributed to caloric loss resulting from increased glucose excretion or to both. A study that aimed to determine whether body weight reduction with dapagliflozin was the result of changes in body composition [23] , showed that reduction in fat mass accounted for approximately two-thirds of the total weight loss. The changes in body weight and fat mass with dapagliflozin were sustained for a total of 102 weeks of treatment, at which time placebocorrected weight loss was 2.4 kg and reduction in fat mass accounted for 68% of the reduction in body weight [24] .
Osmotic diuresis may be responsible for the initial reduction in body weight; however, the subsequent weight loss is the result of caloric output via glucose excretion [22] .
Dapagliflozin as an add-on or in combination with other antidiabetic agents also consistently produced modest reductions in blood pressure, probably as the result of the same mild diuretic-like effect [22] . In patients with T2DM and hypertension being treated with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), dapagliflozin 10 mg/day significantly reduced seated systolic blood pressure versus placebo by 3.1 mm Hg after 12 weeks of treatment [25] . In a similarly designed 12-week study in patients with hypertension and T2DM receiving an ACEi or ARB, and a second antihypertensive agent, dapagliflozin 10 mg/day significantly reduced seated systolic blood pressure versus placebo by 4.3 mmHg [26] .
The effects of SGLT2 inhibitors on hyperglycemia, body weight, and blood pressure suggest a positive effect on CV risk factors. Favourable CV results for another SGLT2 inhibitor, empagliflozin, were presented at EASD meeting in 2015 [27] and published almost simultaneously in the New England Journal of Medicine [28] . The results of EMPA-REG OUTCOME study demonstrate the achievement of the pre-defined primary endpoint (3-point MACE (major adverse cardiac events); a composite of cardiovascular death, non-fatal stroke, and non-fatal myocardial infarction reduction) [27, 28] . Dapagliflozin has a similar mode of action with empagliflozin, and it can be hypothesised that CV protection might be a class effect. However, conclusive results are expected to be available in 2019, when a large CV outcome study with dapagliflozin (DECLARE TIMI-58) will be completed [9] . Until then, a very recently published meta-analysis of data from 9339 patients (5936 treated with dapagliflozin 2.5-10 mg) showed that dapagliflozin is not associated with increased CV risk. Moreover, data show that dapagliflozin is associated with a beneficial effect in the overall population (HR for MACE 0.77; 95%CI 0.54, 1.10) and in those with a history of CV disease (HR for MACE 0.80; 95% CI 0.53, 1.22) [29] .
Safety and tolerability of dapagliflozin treatment
In clinical trials with dapagliflozin, the majority of treatment-emergent adverse events were mild to moderate in intensity.
The incidence of hypoglycemia with dapagliflozin 10 mg was low and similar to that with placebo. Hypoglycemic events were reported more frequently with dapagliflozin than with placebo when dapagliflozin was added on to insulin (54% vs. 52%) or glimepiride (8% vs. 5%) [18] or as add-on to metformin plus an SU (13% versus 4%) [17] . Importantly, incidence of hypoglycaemia was nearly 10-fold less with dapagliflozin (3.4%) compared with glipizide (39.7%) as add-on therapy to metformin [30] . Severe hypoglycaemia (defined as symptomatic episodes in which the patient required external assistance owing to severe impairment in consciousness or behaviour, plasma glucose concentration <54 mg/dL, and promptly recovered after receiving glucose or glucagon) was very rare with dapagliflozin [30] .
Hyperglycemia and diabetes are associated with an increased risk of genital and urinary tract infections (UTI) [30] . In data pooled from 12 double-blind clinical trials of dapagliflozin, confirmed cases of genital infections were more frequent in patients receiving dapagliflozin 10 mg/day (5%) than in those receiving placebo or comparator (1%) [30] . Genital infections were more common in women than in men, and in patients with a history of recurrent genital infections. This increase in uro-genital infections was described for all SGLT2 inhibitors and thus it appears to be a class effect [30] .
The tolerability profile demonstrated in the short-term studies was maintained consistently in patients receiving long-term dapagliflozin treatment. No substantial adverse effects on serum electrolytes, liver function, or renal function were reported. In general, there was a transient decrease in eGFR during the first weeks of dapagliflozin treatment, followed by a return to baseline levels or higher [30] . Overall, there was no evidence of new or worsening renal impairment, acute nephrotoxicity, or progression of diabetic renal disease in dapagliflozin-treated patients at up to 2 years. Recent findings from routine clinical practice confirm that dapagliflozin therapy is not associated with nephrotoxicity [30] .
Volume-related events, like hypotension, dehydration and hypovolemia, were infrequent and none was serious, but occurred more often in the dapagliflozin group (0.8 %) compared with placebo (0.4 %). There was a higher risk of volume depletion events for dapagliflozin compared with placebo in patients also receiving loop diuretics (6.1 vs. 1.8 %, respectively). Numerically higher rates of dyslipidemia with dapagliflozin versus placebo have been reported, with small elevations in total cholesterol, lowdensity lipoprotein cholesterol and high-density lipoprotein cholesterol, and reductions in triglycerides [30] .
Rare cases of diabetic ketoacidosis have occurred in patients taking SGLT2 inhibitors for type 2 diabetes, with a number of atypical cases including patients not having blood sugar levels as high as expected. It can be assumed that this is a class effect due to inappropriate prescriptions in patients with insufficient insulin. In February 2016, the European Medicines Agency recommended the update of the product information of SGLT2 inhibitors by listing diabetic ketoacidosis as a rare adverse event, affecting up to one in 1000 patients [31] . Nonetheless, the benefits of these medicines continue to outweigh the risks in the treatment of type 2 diabetes.
Discussions
Current guidelines for type 2 diabetes patients recommend achievement and maintenance of HbA1c target of approximately 7%, with the help of a personalized treatment approach [3] .
SGLT2 inhibitors provide key clinical benefits in patients with T2DM: maintenance of glycemic control and weight loss. The risk of major hypoglycemic events is low, given the fact that these agents do not interfere with normal endogenous glucose production in response to hypoglycemia or stimulate insulin release. Cardiovascular benefit was demonstrated for empagliflozin and is anticipated also for dapagliflozin, as a class effect.
Dapagliflozin is effective as monotherapy or as an add-on to insulin or any other oral antidiabetic agent, and has proven effects of reducing both body weight and blood pressure. Clinical trials published to date have shown that dapagliflozin is effective and safe in patients with T2DM, both as monotherapy and in combination with other glucose-lowering agents, while data reporting 4-years of clinical experience support these findings. Dapagliflozin is effective in both early and late stages of T2DM, despite differences in disease status and concomitant medications, suggesting that the insulin-independent mechanism of action of dapagliflozin could make it a suitable treatment option throughout the different stages of clinical progression of T2DM.
Conclusions
Dapagliflozin is an efficient, safe and thus reliable second-line treatment for T2DM, after metformin. Besides the anti-hyperglycemic effect, treatment with dapagliflozin has a beneficial impact on cardiovascular risk factors: systolic, diastolic blood pressure and patient's weight, all these outcomes being obtained in parallel with a good safety profile.
